{
    "nctId": "NCT02734615",
    "briefTitle": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers",
    "officialTitle": "A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy",
    "overallStatus": "TERMINATED",
    "conditions": "Advanced or Metastatic ER+ Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 199,
    "primaryOutcomeMeasure": "Incidence of dose limiting toxicities (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent must be obtained prior to any procedures\n* Histologically and/or cytologically confirmed diagnosis of ER+/HER2- breast cancer\n* Advanced or metastatic breast cancer\n* Must be able to swallow tablets and capsules\n\nExclusion Criteria:\n\n* Symptomatic CNS metastases\n* Patients whose laboratory values do not meet protocol criteria\n* Clinically significant cardiac disease\n* Impaired gastrointestinal function (GI) or GI disease that may significantly alter the absorption of oral medications\n\nOther protocol defined inclusion/exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}